166 related articles for article (PubMed ID: 37649102)
21. Serum Hepcidin and GDF-15 levels as prognostic markers in urothelial carcinoma of the upper urinary tract and renal cell carcinoma.
Traeger L; Ellermann I; Wiethoff H; Ihbe J; Gallitz I; Eveslage M; Moritz R; Herrmann E; Schrader AJ; Steinbicker AU
BMC Cancer; 2019 Jan; 19(1):74. PubMed ID: 30646851
[TBL] [Abstract][Full Text] [Related]
22. Impact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease.
Ueda N; Takasawa K
Nutrients; 2018 Aug; 10(9):. PubMed ID: 30150549
[TBL] [Abstract][Full Text] [Related]
23. Hepcidin Response to Iron Therapy in Patients with Non-Dialysis Dependent CKD: An Analysis of the FIND-CKD Trial.
Gaillard CA; Bock AH; Carrera F; Eckardt KU; Van Wyck DB; Bansal SS; Cronin M; Meier Y; Larroque S; Roger SD; Macdougall IC
PLoS One; 2016; 11(6):e0157063. PubMed ID: 27276035
[TBL] [Abstract][Full Text] [Related]
24. Serum hepcidin and growth differentiation factor-15 (GDF-15) levels in polycythemia vera and essential thrombocythemia.
Tarkun P; Mehtap O; Atesoğlu EB; Geduk A; Musul MM; Hacihanefioglu A
Eur J Haematol; 2013 Sep; 91(3):228-235. PubMed ID: 23731455
[TBL] [Abstract][Full Text] [Related]
25. Hepcidin in chronic kidney disease: not an anaemia management tool, but promising as a cardiovascular biomarker.
van der Weerd NC; Grooteman MP; Nubé MJ; ter Wee PM; Swinkels DW; Gaillard CA
Neth J Med; 2015 Mar; 73(3):108-18. PubMed ID: 25852110
[TBL] [Abstract][Full Text] [Related]
26. Transforming growth factor 15 increased in severe aplastic anemia patients.
Shao Y; Wang H; Liu C; Cao Q; Fu R; Wang H; Wang T; Qi W; Shao Z
Hematology; 2017 Oct; 22(9):548-553. PubMed ID: 28385068
[TBL] [Abstract][Full Text] [Related]
27. Bone marrow macrophage iron content and sideroblast count in iron- and ESA-naïve patients with CKD-related anemia.
Capusa C; Mehedinti AM; Bârsan L; Stanciu A; Calenic A; Mircescu G
Ren Fail; 2023 Dec; 45(1):2230300. PubMed ID: 37408484
[TBL] [Abstract][Full Text] [Related]
28. GDF-15 and Hepcidin Levels in Nonanemic Patients with Impaired Glucose Tolerance.
Yalcin MM; Altinova AE; Akturk M; Gulbahar O; Arslan E; Ors Sendogan D; Yetkin I; Toruner FB
J Diabetes Res; 2016; 2016():1240843. PubMed ID: 27642607
[TBL] [Abstract][Full Text] [Related]
29. Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial.
Gummer J; Trengove R; Pascoe EM; Badve SV; Cass A; Clarke P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM; Johnson DW; Olynyk JK; Ferrari P;
Nephrology (Carlton); 2017 Jul; 22(7):548-554. PubMed ID: 27171136
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of Hepcidin and Atherosclerosis in Dialysis Patients.
Manolov V; Petrova J; Bogov B; Hadjidekova S; Vasilev V; Yonova D; Petrova M; Kunchev T; Jelev Y; Jeliazkov P; Marinov B; Bogov I; Gramatikova Z; Voleva S; Tzatchev K; Traykov L
Clin Lab; 2017 Nov; 63(11):1787-1792. PubMed ID: 29226654
[TBL] [Abstract][Full Text] [Related]
31. Bone marrow iron distribution, hepcidin, and ferroportin expression in renal anemia.
Bârsan L; Stanciu A; Stancu S; Căpuşă C; Brătescu L; Mandache E; Radu E; Mircescu G
Hematology; 2015 Oct; 20(9):543-52. PubMed ID: 25745821
[TBL] [Abstract][Full Text] [Related]
32. Serum hepcidin-25 and response to intravenous iron in patients with non-dialysis chronic kidney disease.
Chand S; Ward DG; Ng ZY; Hodson J; Kirby H; Steele P; Rooplal I; Bantugon F; Iqbal T; Tselepis C; Drayson MT; Whitelegg A; Chowrimootoo M; Borrows R
J Nephrol; 2015 Feb; 28(1):81-8. PubMed ID: 24687402
[TBL] [Abstract][Full Text] [Related]
33. GDF15 is related to anemia and hepcidin in kidney allograft recipients.
Malyszko J; Koc-Zorawska E; Malyszko JS; Glowinska I; Mysliwiec M; Macdougall IC
Nephron Clin Pract; 2013; 123(1-2):112-7. PubMed ID: 23797049
[TBL] [Abstract][Full Text] [Related]
34. Hepcidin-25 in diabetic chronic kidney disease is predictive for mortality and progression to end stage renal disease.
Wagner M; Ashby DR; Kurtz C; Alam A; Busbridge M; Raff U; Zimmermann J; Heuschmann PU; Wanner C; Schramm L
PLoS One; 2015; 10(4):e0123072. PubMed ID: 25894587
[TBL] [Abstract][Full Text] [Related]
35. Study of anemia in nondialysis dependent chronic kidney disease with special reference to serum hepcidin.
Goyal H; Mohanty S; Sharma M; Rani A
Indian J Nephrol; 2017; 27(1):44-50. PubMed ID: 28182038
[TBL] [Abstract][Full Text] [Related]
36. Utility of reticulocyte haemoglobin content and percentage hypochromic red cells as markers of iron deficiency anaemia among black CKD patients in South Africa.
Nalado AM; Mahlangu JN; Duarte R; Paget G; Olorunfemi G; Jacobson BF; Naicker S
PLoS One; 2018; 13(10):e0204899. PubMed ID: 30281654
[TBL] [Abstract][Full Text] [Related]
37. Hepcidin-25 concentrations are markedly increased in patients with chronic kidney disease and are inversely correlated with estimated glomerular filtration rates.
Troutt JS; Butterfield AM; Konrad RJ
J Clin Lab Anal; 2013 Nov; 27(6):504-10. PubMed ID: 24218134
[TBL] [Abstract][Full Text] [Related]
38. Hepcidin in chronic kidney disease anemia.
Santos-Silva A; Ribeiro S; Reis F; Belo L
Vitam Horm; 2019; 110():243-264. PubMed ID: 30798815
[TBL] [Abstract][Full Text] [Related]
39. Growth differentiation factor 15 is related to anemia and iron metabolism in heart allograft recipients and patients with chronic heart failure.
Przybyłowski P; Wasilewski G; Bachorzewska-Gajewska H; Golabek K; Dobrzycki S; Małyszko J
Transplant Proc; 2014 Oct; 46(8):2852-5. PubMed ID: 25380934
[TBL] [Abstract][Full Text] [Related]
40. Hepcidin, iron indices and bone mineral metabolism in non-dialysis chronic kidney disease.
Min HK; Sung SA; Oh YK; Kim YH; Chung W; Park SK; Ahn C; Lee SW
Nephrol Dial Transplant; 2020 Jan; 35(1):147-154. PubMed ID: 30053139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
